Not yet recruiting
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
NCT07858123· Phase 3· Chiesi Farmaceutici S.p.A.· Source
Not yet recruiting
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
NCT07116473· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source
Recruiting
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07465289· Phase 3· UCB Biopharma SRL· Source
Not yet recruiting
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00· Phase 2/3· Azienda Sanitaria Locale Napoli 1 Centro· Source
Recruiting
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
NCT07626411· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
NCT07318610· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
Open Label Extension to Assess Long Term Safety and Efficacy of KL1333 in Patients With Primary Mitochondrial Disease
NCT07514338· Phase 2· Pharming Technologies B.V.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521· Phase 3· UCB Biopharma SRL· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
NCT07554495· Phase 3· Alfasigma S.p.A.· Source
Recruiting
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001· Phase 3· Novo Nordisk A/S· Source
Recruiting
Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY
2025-523367-38-00· Phase 3· Medivis S.r.l.· Source
Recruiting
A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
2025-523079-44-00· Phase 3· Ascendis Pharma Endocrinology Division A/S· Source
Recruiting
KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases
NCT06451757· Phase 3· Khondrion BV· Source
Recruiting
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
NCT07223203· Phase 3· Alnylam Pharmaceuticals· Source
Recruiting
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT06405087· Phase 3· Takeda· Source
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes
NCT07112339· Phase 4· Novo Nordisk A/S· Source
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827· Phase 3· Takeda· Source
Recruiting
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
NCT06409936· Phase 2· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895· Phase 3· Eidos Therapeutics, a BridgeBio company· Source
Recruiting
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
NCT06747351· Phase 3· Takeda· Source
Not yet recruiting
Ultra-hypofractionated radiotHErapy and concomitant oral RelugOlix for treatment of intermediate risk prostate cancer. (Ultra-HERO trial)
2024-518388-37-00· Phase 2· Fondazione Radioterapia Oncologica Onlus· Source
Recruiting
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
NCT06100289· Phase 3· Takeda· Source
Not yet recruiting
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
NCT06618937· Phase 4· Istituto Giannina Gaslini· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source
Recruiting
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
2024-511184-28-00· Phase 2· Splisense Ltd.· Source
Recruiting
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT06275919· Phase 2· Istituto Oncologico Veneto IRCCS· Source
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· Phase 2· AbbVie· Source
Active, not recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534· Phase 3· AbbVie· Source
Active, not recruiting
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
NCT06290128· Phase 3· Sanofi· Source
Active, not recruiting
A Trial of Lu AG13909 in Adult Participants With Cushing's Disease
NCT06471829· Phase 2· H. Lundbeck A/S· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP
NCT06423911· Phase 3· Ascentage Pharma Group Inc.· Source
Active, not recruiting
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250· Phase 3· Tenax Therapeutics, Inc.· Source
Recruiting
Early reduction of antiplatelet therapy in patients with Acute Coronary Syndrome treated with stent implantation and at high risk of bleeding.
2023-509868-20-00· Phase 3· Azienda Ospedaliera Universitaria Gaetano Martino Messina· Source
Recruiting
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
NCT04662723· Phase 4· Fondazione Schena· Source
Active, not recruiting
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855· Phase 3· Scholar Rock, Inc.· Source
Recruiting
Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease
NCT05650229· Phase 2· Pharming Technologies B.V.· Source
Active, not recruiting
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis
2024-515557-22-00· Phase 4· Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico· Source
Recruiting
Riluzole in spinocerebellar ataxia type 7
2024-518962-29-00· Phase 2· Universita Degli Studi Di Roma La Sapienza· Source
Active, not recruiting
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
NCT04722848· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Not yet recruiting
A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with pleural mesothelioma positive for PD-L1 expression and germline or somatic mutations in the HRR genes
NCT04940637· Phase 2· Universita' Degli Studi Di Torino· Source
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
NCT04168502· Phase 3· Gruppo Italiano Malattie EMatologiche dell'Adulto· Source
Active, not recruiting
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718· Phase 2· argenx· Source
Active, not recruiting
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· Phase 3· Madrigal Pharmaceuticals Inc.· Source
Showing 50 of 52.